180 related articles for article (PubMed ID: 37440099)
21. Occurrence and Severity of Suicidal Ideation in Adults With Neurofibromatosis Participating in a Mind-Body RCT.
Lester EG; Wang KE; Blakeley JO; Vranceanu AM
Cogn Behav Neurol; 2023 Mar; 36(1):19-27. PubMed ID: 36651958
[TBL] [Abstract][Full Text] [Related]
22. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
23. A Virtual Resiliency Intervention Promoting Resiliency for Parents of Children with Learning and Attentional Disabilities: A Randomized Pilot Trial.
Park ER; Perez GK; Millstein RA; Luberto CM; Traeger L; Proszynski J; Chad-Friedman E; Kuhlthau KA
Matern Child Health J; 2020 Jan; 24(1):39-53. PubMed ID: 31650412
[TBL] [Abstract][Full Text] [Related]
24. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
25. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial.
Lester E; DiStefano S; Mace R; Macklin E; Plotkin S; Vranceanu AM
Gen Hosp Psychiatry; 2020; 62():72-78. PubMed ID: 31841875
[TBL] [Abstract][Full Text] [Related]
26. The development of a patient-centered program based on the relaxation response: the Relaxation Response Resiliency Program (3RP).
Park ER; Traeger L; Vranceanu AM; Scult M; Lerner JA; Benson H; Denninger J; Fricchione GL
Psychosomatics; 2013; 54(2):165-74. PubMed ID: 23352048
[TBL] [Abstract][Full Text] [Related]
27. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
28. Testing psychosocial mediators of a mind-body resiliency intervention for cancer survivors.
Finkelstein-Fox L; Rasmussen AW; Hall DL; Perez GK; Comander AH; Peppercorn J; Anctil R; Wang C; Park ER
Support Care Cancer; 2022 Jul; 30(7):5911-5919. PubMed ID: 35386004
[TBL] [Abstract][Full Text] [Related]
29. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis.
Pietrzykowski MO; Vranceanu AM; Macklin EA; Mace RA
Qual Life Res; 2024 May; 33(5):1233-1240. PubMed ID: 38214851
[TBL] [Abstract][Full Text] [Related]
30. Effect of the Promoting Resilience in Stress Management Intervention for Parents of Children With Cancer (PRISM-P): A Randomized Clinical Trial.
Rosenberg AR; Bradford MC; Junkins CC; Taylor M; Zhou C; Sherr N; Kross E; Curtis JR; Yi-Frazier JP
JAMA Netw Open; 2019 Sep; 2(9):e1911578. PubMed ID: 31532518
[TBL] [Abstract][Full Text] [Related]
31. Resilience@Work Mindfulness Program: Results From a Cluster Randomized Controlled Trial With First Responders.
Joyce S; Shand F; Lal TJ; Mott B; Bryant RA; Harvey SB
J Med Internet Res; 2019 Feb; 21(2):e12894. PubMed ID: 30777846
[TBL] [Abstract][Full Text] [Related]
32. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
33. Effects of a mind-body program on symptoms of depression and perceived stress among adults with neurofibromatosis type 2 who are deaf: A live-video randomized controlled trial.
Carter S; Greenberg J; Funes CJ; Macklin EA; Vranceanu AM
Complement Ther Med; 2021 Jan; 56():102581. PubMed ID: 33197677
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the Promoting Resilience in Stress Management Intervention for Adolescent and Young Adult Survivors of Cancer at 2 Years: Secondary Analysis of a Randomized Clinical Trial.
Rosenberg AR; Zhou C; Bradford MC; Salsman JM; Sexton K; O'Daffer A; Yi-Frazier JP
JAMA Netw Open; 2021 Nov; 4(11):e2136039. PubMed ID: 34817581
[TBL] [Abstract][Full Text] [Related]
35. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
36. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
Talaei-Khoei M; Riklin E; Merker VL; Sheridan MR; Jordan JT; Plotkin SR; Vranceanu AM
J Neurooncol; 2017 Jan; 131(2):413-419. PubMed ID: 27900643
[TBL] [Abstract][Full Text] [Related]
37. Promoting Resilience and Flourishing Among Older Adult Residents in Community Living: A Feasibility Study.
Traeger L; Styklunas GM; Park EY; Lee MT; Fricchione G; Park ER
Gerontologist; 2022 Nov; 62(10):1507-1518. PubMed ID: 35235940
[TBL] [Abstract][Full Text] [Related]
38. Feasibility and Efficacy of a Resiliency Intervention for the Prevention of Chronic Emotional Distress Among Survivor-Caregiver Dyads Admitted to the Neuroscience Intensive Care Unit: A Randomized Clinical Trial.
Vranceanu AM; Bannon S; Mace R; Lester E; Meyers E; Gates M; Popok P; Lin A; Salgueiro D; Tehan T; Macklin E; Rosand J
JAMA Netw Open; 2020 Oct; 3(10):e2020807. PubMed ID: 33052404
[TBL] [Abstract][Full Text] [Related]
39. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
[TBL] [Abstract][Full Text] [Related]
40. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
